187 related articles for article (PubMed ID: 32372373)
1. The metalloproteinase ADAM10 requires its activity to sustain surface expression.
Seifert A; Düsterhöft S; Wozniak J; Koo CZ; Tomlinson MG; Nuti E; Rossello A; Cuffaro D; Yildiz D; Ludwig A
Cell Mol Life Sci; 2021 Jan; 78(2):715-732. PubMed ID: 32372373
[TBL] [Abstract][Full Text] [Related]
2. ADAM10-Mediated Ectodomain Shedding Is an Essential Driver of Podocyte Damage.
Sachs M; Wetzel S; Reichelt J; Sachs W; Schebsdat L; Zielinski S; Seipold L; Heintz L; Müller SA; Kretz O; Lindenmeyer M; Wiech T; Huber TB; Lüllmann-Rauch R; Lichtenthaler SF; Saftig P; Meyer-Schwesinger C
J Am Soc Nephrol; 2021 Jun; 32(6):1389-1408. PubMed ID: 33785583
[TBL] [Abstract][Full Text] [Related]
3. The collectrin-like part of the SARS-CoV-1 and -2 receptor ACE2 is shed by the metalloproteinases ADAM10 and ADAM17.
Niehues RV; Wozniak J; Wiersch F; Lilienthal E; Tacken N; Schumertl T; Garbers C; Ludwig A; Düsterhöft S
FASEB J; 2022 Mar; 36(3):e22234. PubMed ID: 35199397
[TBL] [Abstract][Full Text] [Related]
4. Role of ADAM10 in intestinal crypt homeostasis and tumorigenesis.
Dempsey PJ
Biochim Biophys Acta Mol Cell Res; 2017 Nov; 1864(11 Pt B):2228-2239. PubMed ID: 28739265
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of ADAM10 promotes the clearance of Aβ across the BBB by reducing LRP1 ectodomain shedding.
Shackleton B; Crawford F; Bachmeier C
Fluids Barriers CNS; 2016 Aug; 13(1):14. PubMed ID: 27503326
[TBL] [Abstract][Full Text] [Related]
6. Cell-autonomous FLT3L shedding via ADAM10 mediates conventional dendritic cell development in mouse spleen.
Fujita K; Chakarov S; Kobayashi T; Sakamoto K; Voisin B; Duan K; Nakagawa T; Horiuchi K; Amagai M; Ginhoux F; Nagao K
Proc Natl Acad Sci U S A; 2019 Jul; 116(29):14714-14723. PubMed ID: 31262819
[TBL] [Abstract][Full Text] [Related]
7. Proteolytic shedding of the prion protein via activation of metallopeptidase ADAM10 reduces cellular binding and toxicity of amyloid-β oligomers.
Jarosz-Griffiths HH; Corbett NJ; Rowland HA; Fisher K; Jones AC; Baron J; Howell GJ; Cowley SA; Chintawar S; Cader MZ; Kellett KAB; Hooper NM
J Biol Chem; 2019 Apr; 294(17):7085-7097. PubMed ID: 30872401
[TBL] [Abstract][Full Text] [Related]
8. Tetraspanin 3: A central endocytic membrane component regulating the expression of ADAM10, presenilin and the amyloid precursor protein.
Seipold L; Damme M; Prox J; Rabe B; Kasparek P; Sedlacek R; Altmeppen H; Willem M; Boland B; Glatzel M; Saftig P
Biochim Biophys Acta Mol Cell Res; 2017 Jan; 1864(1):217-230. PubMed ID: 27818272
[TBL] [Abstract][Full Text] [Related]
9. Trop-2 cleavage by ADAM10 is an activator switch for cancer growth and metastasis.
Trerotola M; Guerra E; Ali Z; Aloisi AL; Ceci M; Simeone P; Acciarito A; Zanna P; Vacca G; D'Amore A; Boujnah K; Garbo V; Moschella A; Lattanzio R; Alberti S
Neoplasia; 2021 Apr; 23(4):415-428. PubMed ID: 33839455
[TBL] [Abstract][Full Text] [Related]
10. Analysis of the Conditions That Affect the Selective Processing of Endogenous Notch1 by ADAM10 and ADAM17.
Alabi RO; Lora J; Celen AB; Maretzky T; Blobel CP
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33673337
[TBL] [Abstract][Full Text] [Related]
11. The tetraspanin Tspan15 is an essential subunit of an ADAM10 scissor complex.
Koo CZ; Harrison N; Noy PJ; Szyroka J; Matthews AL; Hsia HE; Müller SA; Tüshaus J; Goulding J; Willis K; Apicella C; Cragoe B; Davis E; Keles M; Malinova A; McFarlane TA; Morrison PR; Nguyen HTH; Sykes MC; Ahmed H; Di Maio A; Seipold L; Saftig P; Cull E; Pliotas C; Rubinstein E; Poulter NS; Briddon SJ; Holliday ND; Lichtenthaler SF; Tomlinson MG
J Biol Chem; 2020 Sep; 295(36):12822-12839. PubMed ID: 32111735
[TBL] [Abstract][Full Text] [Related]
12. Proteolytic cleavage of amyloid precursor protein by ADAM10 mediates proliferation and migration in breast cancer.
Tsang JYS; Lee MA; Chan TH; Li J; Ni YB; Shao Y; Chan SK; Cheungc SY; Lau KF; Tse GMK
EBioMedicine; 2018 Dec; 38():89-99. PubMed ID: 30470613
[TBL] [Abstract][Full Text] [Related]
13. GPR37 is processed in the N-terminal ectodomain by ADAM10 and furin.
Mattila SO; Tuhkanen HE; Lackman JJ; Konzack A; Morató X; Argerich J; Saftig P; Ciruela F; Petäjä-Repo UE
FASEB J; 2021 Jun; 35(6):e21654. PubMed ID: 34042202
[TBL] [Abstract][Full Text] [Related]
14. Endoglycan (PODXL2) is proteolytically processed by ADAM10 (a disintegrin and metalloprotease 10) and controls neurite branching in primary neurons.
Hsia HE; Tüshaus J; Feng X; Hofmann LI; Wefers B; Marciano DK; Wurst W; Lichtenthaler SF
FASEB J; 2021 Sep; 35(9):e21813. PubMed ID: 34390512
[TBL] [Abstract][Full Text] [Related]
15. The plasma membrane: Penultimate regulator of ADAM sheddase function.
Reiss K; Bhakdi S
Biochim Biophys Acta Mol Cell Res; 2017 Nov; 1864(11 Pt B):2082-2087. PubMed ID: 28624437
[TBL] [Abstract][Full Text] [Related]
16. Ionizing radiation increases the endothelial permeability and the transendothelial migration of tumor cells through ADAM10-activation and subsequent degradation of VE-cadherin.
Kouam PN; Rezniczek GA; Adamietz IA; Bühler H
BMC Cancer; 2019 Oct; 19(1):958. PubMed ID: 31619190
[TBL] [Abstract][Full Text] [Related]
17. ADAM10 is the major sheddase responsible for the release of membrane-associated meprin A.
Herzog C; Haun RS; Ludwig A; Shah SV; Kaushal GP
J Biol Chem; 2014 May; 289(19):13308-22. PubMed ID: 24662289
[TBL] [Abstract][Full Text] [Related]
18. MT1-MMP and ADAM10/17 exhibit a remarkable overlap of shedding properties.
Werny L; Grogro A; Bickenbach K; Bülck C; Armbrust F; Koudelka T; Pathak K; Scharfenberg F; Sammel M; Sheikhouny F; Tholey A; Linder S; Becker-Pauly C
FEBS J; 2023 Jan; 290(1):93-111. PubMed ID: 35944080
[TBL] [Abstract][Full Text] [Related]
19. Ectodomain shedding of the cell adhesion molecule Nectin-4 in ovarian cancer is mediated by ADAM10 and ADAM17.
Buchanan PC; Boylan KLM; Walcheck B; Heinze R; Geller MA; Argenta PA; Skubitz APN
J Biol Chem; 2017 Apr; 292(15):6339-6351. PubMed ID: 28232483
[TBL] [Abstract][Full Text] [Related]
20. Inhibiting pathologically active ADAM10 rescues synaptic and cognitive decline in Huntington's disease.
Vezzoli E; Caron I; Talpo F; Besusso D; Conforti P; Battaglia E; Sogne E; Falqui A; Petricca L; Verani M; Martufi P; Caricasole A; Bresciani A; Cecchetti O; Rivetti di Val Cervo P; Sancini G; Riess O; Nguyen H; Seipold L; Saftig P; Biella G; Cattaneo E; Zuccato C
J Clin Invest; 2019 May; 129(6):2390-2403. PubMed ID: 31063986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
